Cargando…

Antiplatelet therapy in patients with acute coronary syndromes and thrombocytopaenia: awaiting for evidence

Detalles Bibliográficos
Autores principales:	Liga, Riccardo, De Carlo, Marco, De Caterina, Raffaele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859589/ https://www.ncbi.nlm.nih.gov/pubmed/33569527 http://dx.doi.org/10.1093/ehjcr/ytaa577

Ejemplares similares

Antiplatelet therapy for elderly patients with Acute Coronary Syndromes
por: Savonitto, Stefano, et al.
Publicado: (2018)

Anticoagulation and antiplatelet therapy in acute coronary syndromes: choosing between the Scylla of bleeding and the Charybdis of ischaemic events
por: de Winter, R. J.
Publicado: (2018)

Antiplatelet therapy following TAVI: time to randomise
por: Delewi, R., et al.
Publicado: (2014)

Measuring hospital performance in the management of acute coronary syndromes
por: de Winter, R. J.
Publicado: (2014)

Longer or shorter dual antiplatelet therapy in dialysis patients receiving a coronary drug-eluting stent? A rope game still ongoing
por: Burlacu, Alexandru, et al.
Publicado: (2020)

Tailored Antiplatelet Therapy in Patients Undergoing PCI: Is Rapid Bedside Genetic Testing the Answer?
por: Faxon, David P.
Publicado: (2020)

Awaiting the “catharsis”
por: Yfantopoulos, John
Publicado: (2020)

Trials, registries and guidelines for non-ST-elevation acute coronary syndromes
por: Verheugt, F. W. A.
Publicado: (2013)

Oral manifestations of thrombocytopaenia
por: Khammissa, R.A.G., et al.
Publicado: (2018)

Impact of the first COVID-19 wave on quality of care in acute coronary syndrome – the importance of information for health policy design
por: Infante de Oliveira, Eduardo
Publicado: (2022)

Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes
por: De Rosa, Roberta, et al.
Publicado: (2019)

Antiplatelet therapy in acute coronary syndromes: focus on ticagrelor
por: Birkeland, Kade, et al.
Publicado: (2010)

Duration of dual antiplatelet therapy in acute coronary syndrome
por: Wilson, Simon John, et al.
Publicado: (2017)

Prognostic value of mean platelet volume in patients after acute coronary syndrome
por: Jakl, Martin, et al.
Publicado: (2015)

Coronary slow flow: Electrophysiologic evidence of ischemia?
por: Movahed, M. Reza
Publicado: (2015)

Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant… Or, Rather, Temporary Dual Antiplatelet Therapy?
por: Limbruno, Ugo, et al.
Publicado: (2020)

Changes in neutrophil-lymphocyte and platelet-lymphocyte ratios before and after percutaneous coronary intervention and their impact on the prognosis of patients with acute coronary syndrome
por: Souza Teixeira, Edenilson de, et al.
Publicado: (2023)

Foetal and neonatal alloimmune thrombocytopaenia
por: Kaplan, Cecile
Publicado: (2006)

Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
por: Zeymer, Uwe
Publicado: (2013)

Oral Antiplatelet Therapy for Secondary Prevention of Acute Coronary Syndrome
por: Berger, Jeffrey S.
Publicado: (2018)

Optimal dual antiplatelet therapy strategy in elderly patients with acute coronary syndrome
por: Verdoia, Monica, et al.
Publicado: (2021)

The impact of Covid-19 pandemic on acute coronary syndrome admissions at a tertiary care hospital in Portugal
por: Mimoso, Jorge
Publicado: (2022)

Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues
por: Verdoia, Monica, et al.
Publicado: (2020)

International patterns of dual antiplatelet therapy duration after acute coronary syndromes
por: Bueno, Héctor, et al.
Publicado: (2017)

Escalation and De-Escalation of Antiplatelet Therapy after Acute Coronary Syndrome or PCI: Available Evidence and Implications for Practice
por: Gragnano, Felice, et al.
Publicado: (2022)

The management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: early invasive strategy for all?
por: Arslan, F., et al.
Publicado: (2017)

Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
por: Perazella, Mark A, et al.
Publicado: (2021)

Prolonged double antiplatelet therapy vs association of antiplatelet and low dose of anticoagulant therapy: PEGASUS or COMPASS?
por: Brunetti, Natale Daniele, et al.
Publicado: (2019)

Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective
por: Tersalvi, Gregorio, et al.
Publicado: (2020)

Multiterritorial strokes in the setting of spontaneous heparin-induced thrombocytopaenia syndrome
por: Kwan, Christopher, et al.
Publicado: (2022)

Heparin-induced thrombocytopaenia presenting as acute aortic mural thrombosis
por: Bienz, Maya Joanne, et al.
Publicado: (2018)

Coronary artery calcification: does it predict obstructive coronary artery disease?
por: Dharampal, A. S., et al.
Publicado: (2013)

Antiplatelet Strategies for Older Patients with Acute Coronary Syndromes: Finding Directions in a Low-Evidence Field
por: De Servi, Stefano, et al.
Publicado: (2023)

Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?
por: Akin, Ibrahim, et al.
Publicado: (2022)

Anaesthetic management of parturient with malaria and thrombocytopaenia
por: Khanna, Ashish, et al.
Publicado: (2016)

Severe thrombocytopaenia secondary to COVID-19
por: Patel, Trupesh, et al.
Publicado: (2020)

Platelet Reactivity in Hepatitis C Virus–Infected Patients on Dual Antiplatelet Therapy for Acute Coronary Syndrome
por: Scudiero, Fernando, et al.
Publicado: (2020)

High Residual Platelet Activity in Response to Acetylsalicylic Acid in Acute Coronary Syndrome: A New Challenge for Antiplatelet Treatment?
por: Sobral Filho, Dário C., et al.
Publicado: (2019)

Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?
por: van de Loo, Fons A, et al.
Publicado: (2009)

Comment on Savioli et al. Mild Head Trauma: Is Antiplatelet Therapy a Risk Factor for Hemorrhagic Complications? Medicina 2021, 57, 357
por: Lorenzati, Bartolomeo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c5bpjuo4m8vuk0hj9us9dfigra